AI Article Synopsis

  • The study aimed to compare the real-world dosage adjustments of risankizumab to other FDA-approved biologic treatments for moderate-to-severe psoriasis in the U.S. //! -
  • Researchers analyzed data from a large database to identify patients and assess instances where doses exceeded expected levels by 30% or more during treatment. //! -
  • Results showed that only 2.0% of risankizumab patients required dose escalations, significantly lower than those on other biologics, indicating better dosage stability with risankizumab.

Article Abstract

Aim: To compare real-world dose escalation of risankizumab with other US Food and Drug Administration (FDA)-approved biologic treatments for management of moderate-to-severe psoriasis (PsO) in the United States.

Methods: The Merative® MarketScan® Research Database was used to identify adults with ≥2 medical claims for PsO, ≥3 claims of the index biologic medication in the maintenance period, and ≥6 months continuous enrollment pre-induction and ≥6 months after initiation of the maintenance period. Dose escalation was defined as ≥2 dosing intervals where the average daily dose was ≥30% higher than the expected daily dose (per FDA-approved dosing). Comparisons between risankizumab and other cohorts were made using chi-square tests and logistic regression models.

Results: At the 30% threshold, the percentage of patients with dose escalation in the full maintenance period was significantly lower with risankizumab (2.0%) compared with other drug classes (tumor necrosis factor, interleukin (IL)-12/23, IL-17, or other IL-23 inhibitors: 17.6%, 10.0%, 18.3%, or 7.1%, respectively;  < 0.0001 for each) and individual biologics (adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab; 17.9%, 10.0%, 15.7%, 18.0%, and 7.2%, respectively;  < 0.0001).

Conclusion: A significantly lower proportion of risankizumab-treated patients with PsO had dose escalations compared with patients treated with other biologics.

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2023.2200869DOI Listing

Publication Analysis

Top Keywords

dose escalation
16
maintenance period
12
real-world dose
8
moderate-to-severe psoriasis
8
daily dose
8
dose
5
escalation
4
escalation biologics
4
biologics moderate-to-severe
4
psoriasis united
4

Similar Publications

Allergen-specific immunotherapy is the only etiological treatment that can prevent the progression of allergic diseases at present. Cluster immunotherapy is an improved immunotherapy regimen, which shortens the dose escalation period from 4-6 months in conventional regimen to 1-8 weeks. In the past, there was no consensus or guideline to guide the standardized application of subcutaneous cluster immunotherapy of inhaled allergens in China.

View Article and Find Full Text PDF

Background: Many patients with head and neck cancer are not candidates for standard of care definitive treatments though often require palliative treatments given the frequent symptoms associated with head and neck cancer. While existing palliative radiotherapy regimens can provide adequate symptom control, they have limitations particularly with respect to local control which is becoming more important as advances in systemic therapy are improving survival. Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) is a novel radiotherapy regimen which leverages advances in radiotherapy treatment technology and extended interfraction intervals to enable adaptive radiotherapy and possible synergy with the immune system.

View Article and Find Full Text PDF

Background: Pleural carcinosis originates from various cancers. Its management consists in systemic therapies combined to dyspnea relief procedures. Prior studies have tested hyperthermic intrathoracic chemotherapy to treat pleural carcinosis with interesting patient survival results.

View Article and Find Full Text PDF

The Efficacy of Cecropin Against Multidrug-Resistant Bacteria Is Linked to the Destabilization of Outer Membrane Structure LPS of Gram-Negative Bacteria.

Probiotics Antimicrob Proteins

December 2024

National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing, China.

The escalating prevalence of antibiotic-resistant bacteria has emerged as a formidable threat to global health, and the quest for alternative antimicrobial agents is imperative. Cecropins, a class of antimicrobial peptides (AMPs), have garnered attention due to their potent bactericidal properties. This investigation delves into the antibacterial prowess of Cecropin A (CA) and Cecropin AD (CAD), showcasing their robust activity against Gram-negative bacteria, inclusive of multidrug-resistant bacteria.

View Article and Find Full Text PDF

Allogeneic umbilical cord-derived mesenchymal stromal cells as treatment for systemic lupus erythematosus: a single-centre, open-label, dose-escalation, phase 1 study.

Lancet Rheumatol

December 2024

SITI, CHU Rennes, Etablissement Français du Sang Bretagne, Rennes, France; INSERM UMR 1236, Université Rennes, INSERM, Etablissement Français du Sang Bretagne, Rennes, France. Electronic address:

Background: Patients with systemic lupus erythematosus (SLE) with inadequate responses to standard therapies have unmet therapeutic needs. The immunomodulatory, proangiogenic, and antifibrotic properties of mesenchymal stromal cells support their use in treating patients with SLE. We aimed to assess the safety of a single intravenous infusion of allogeneic umbilical cord-derived mesenchymal stromal cells in patients with severe SLE.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!